Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > On the positive side

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Oct 13, 2022 3:27pm

134 Views

Post# 35023201

RE:RE:RE:RE:RE:On the positive side

That's a good point, but I still think THTX would be reluctant to go on a road show if they felt strongly they didn't have anything or had any inclination that they might need to pull the plug on the program. Maybe they only talk in detail about Trogarzo and Egrifta.

qwerty22 wrote:
So back to this point. These people they are meeting we can assume no little to nothing about THTX. They didn't need data today to tell the story. It seems pretty OK for them to be filled in on older news and for that to be something to think about. I don't know these people need fresh info like us.

mikeq113 wrote: And why schedule a non-deal road show with Truist if all you have to talk about is that everything is moving along as planned??